Sodium-glucose cotransporter inhibition in polycystic kidney disease: fact or fiction


Creative Commons License

AFŞAR B. , ELSÜRER AFŞAR R. , Demiray A., Altay S., KORKMAZ H. , YILDIZ A., ...More

CLINICAL KIDNEY JOURNAL, 2022 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Review
  • Publication Date: 2022
  • Doi Number: 10.1093/ckj/sfac029
  • Title of Journal : CLINICAL KIDNEY JOURNAL
  • Keywords: apoptosis, autophagy, canagliflozin, dapagliflozin, polycystic kidney disease, SGLT inhibitors, PROGRESSION, DAPAGLIFLOZIN, METFORMIN, RATS, PATHOPHYSIOLOGY, VASOPRESSIN, SECRETION, TOLVAPTAN, GROWTH, POTENT

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease. Recent evidence suggests that the pathogenesis of ADPKD is a complex web of abnormal cellular processes including altered cell signaling, disordered cell metabolism, impaired autophagy, increased apoptosis, mitochondrial dysfunction and chronic inflammation. Sodium-glucose cotransporter (SGLT) inhibitors (SGLTi) reduce body weight, blood pressure and blood glucose levels, have kidney and cardiovascular protective activity, and have been reported to decrease inflammation, increase autophagy and improve mitochondrial dysfunction. We now review results from preclinical studies on SGLTi for ADPKD identified through a systematic search of the MEDLINE, Cochrane Library, Embase and PubMed databases. Potential underlying mechanisms for the conflicting results reported as well as implications for clinical translation are discussed, as ADPKD patients were excluded from clinical trials exploring kidney protection by SGLT2 inhibitors (SGLT2i). However, they were not excluded from cardiovascular safety trials or trials for cardiovascular conditions. A post-hoc analysis of the kidney function trajectories and safety of SGLT2i in ADPKD patients enrolled in such trials may provide additional information. In conclusion, SGLT2i are cardio- and nephroprotective in diverse clinical situations. Currently, it is unclear whether ADPKD patients may benefit from SGLT2i in terms of kidney function preservation, and their safety in this population remains unexplored. We propose a roadmap to address this unmet clinical need.